The risks of not intervening in pre-onset psychotic illness

Journal of Mental Health

Volumn 12, Issue 4, 2003, Pages 345-349

  Miller, Tandy J ^a   McGlashan, Thomas H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; TAMOXIFEN;

CANCER; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; IMPOTENCE; NOTE; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOSOCIAL WITHDRAWAL; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VAGINA ATROPHY; WEIGHT GAIN;

EID: 0041823560     PISSN: 09638237     EISSN: None     Source Type: Journal    
DOI: 10.1080/0963823031000153493     Document Type: Note

References (18)

1. Cuzik, J. (2000). Future Possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Research, 2(4), 258-263.
2. Cuzik, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S. & Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361(9354), 296-300.
3. Falloon, I.R.H. (1992). Early identification for first episodes of schizophrenia: A preliminary exploration. Psychiatry, 55, 4-15.
4. Hafner, H. & van der Heiden, W. (1997). Epidemiology of schizophrenia. Canandian Journal of Psychiatry, 42, 139-151.
5. Hawkins, K.A., Addington, J., Christensen, B., Keefe, R. & McGlashan, T.H. (2002). Neuropsychological status of the first episode prodrome. Symposium, Third International Conference on Early Psychosis, Sept 25-28, 2002 Copenhagen. Acta Psychiatrica Scandinavica, 106(413), 43.
6. McFarlane, W.R. (2003). The Multifamily Group. New York: Guilford Press, in press.
7. McGlashan, T.H. (2001). Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research, 51, 47-54.
8. McGlashan, T.H. & Hoffman, R.E. (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Archives of General Psychiatry, 57, 637-648.
9. McGlashan, T.H. & Johhannessen, J.O. (1996). Early detection and intervetion with shcizophrenia: Rationale. Schizophrenia Bulletin, 22(2), 201-222.
10. McGlashan, T.H., Miller, T.J. & Woods, S.W. (2001). Pre-onset detection and intervention research in schizophrenic psychosis: Current estimates of benefit and risk. Schizophrenia Bulletin, 27(4), 563-570.
11. McGlashan, T.H., Zipursky, R.B., Perkins, D., Addington, J., Miller, T.J., Woods, S.W., Hawkins, K.A., Hoffman, R., Lindborg, S., Tohen, M. & Breier, A. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine vs placebo in patients at risk for being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophrenia Research, 61, 7-18.
12. Miller, T.J., Woods, S.W., Rosen, J.L. & McGlashan, T.H. (2002). Treatment of schizophrenic psychosis at onset (letter). American Journal of Psychiatry, 159(1), 153.
13. Miller, T.J., Zipursky, R.B., Perkins, D., Addington, J., Woods, S.W., Hawkins, K.A., Hoffman, R., Preda, A., Epstein, I., Addington, D., Lindborg, S., Marquez, E., Tohen, M., Breier, A. & McGlashan, T.H., (2003). The PRIME North America randomized double-blind clinical trial of olanzapine vs placebo in patients at risk of being prodromally symptomatic for psychosis: II. Baseline characteristics of the 'prodromal' sample. Schizophrenia Research, 61, 19-30.
14. Preda, A., Miller, T.J., McGlashan, T.H. & Woods, S.W. (2002). Treatment history of patients in schizophrenic prodromal states. Psychiatric Services, 53(3), 342-344.
15. Rosen, J.L., Woods, S.W., Miller, T.J. & McGlashan, T.H. (2002). Prospective observations of emerging psychosis. The Journal of Nervous and Mental Disorders, 190, 133-141.
16. Woods, S.W., Breier, A., Zipursky, R.B., Perkins, D.O., Addington, J., Miller, T.J., Hawkins, K.A., Marquez, E., Lindborg, S.R., Tohen, M. & McGlashan, T.H. (2003). Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of patients meeting criteria for the schizphrenia prodrome. Biological Psychiatry (in press).
17. Yung, A.R., McGorry, P.D., McFarlane, C.A., Jackson, H.J., Patton, G.C. & Rakkar, A. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22(2), 283-303.
18. Yung, A., Phillips, L., McGorry, P., McFarlane, C., Francey, S. & Harrigan, S. (1998). Prediction of psychosis. British Journal of Psychiatry, 172(Suppl. 33), 14-20.